Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Who next in antibiotic M&A gold rush?

This article was originally published in Scrip

Executive Summary

Shares in companies engaged in antibiotic development basked in the reflected glow of Merck & Co's just announced $9.5bn takeout deal for Cubist Pharmaceuticals (scripintelligence.com, 9 December 2014). This acquisition follows hot on the heels of Actavis's $675-820m purchase agreement for fellow antibiotics player Durata Therapeutics (scripintelligence.com, 7 October 2014), and is only the most ostentatious example of a deal-making trend that has been gathering pace over the past year or so.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel